Pure 99% Roflumilast Powder API CAS 162401-32-3 Roflumilast

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: API
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Roflumilast
• CAS: 162401-32-3
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

 

Roflumilast is a selective PDE4 inhibitor with applications in the treatment of respiratory diseases such as COPD and asthma. Its primary function is to reduce inflammation by inhibiting PDE4 enzymes and increasing the levels of cAMP and cGMP, leading to bronchodilation, improved mucus clearance, and overall improvement in lung function.

Product Name	Roflumilast
Appearance	White Powder
CAS NO.	162401-32-3
MF	C17H14Cl2F2N2O3
Storage	Keep in a cool, dry, dark location

1. Chronic Obstructive Pulmonary Disease (COPD): Roflumilast is approved for the treatment of COPD, a long-term lung disease characterized by airflow limitation. It helps to reduce inflammation and improve lung function in patients with this condition.
2. Asthma Management: Although not primarily indicated for asthma, roflumilast may be used in some cases as an add-on therapy to manage asthma, particularly in patients with severe or uncontrolled asthma.
3. Inflammatory Conditions: Due to its anti-inflammatory properties, roflumilast may have potential applications in other inflammatory conditions beyond respiratory diseases, although further research is needed to explore these possibilities.

1. PDE4 Inhibition: Roflumilast selectively inhibits PDE4 enzymes, which are involved in the degradation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). By inhibiting PDE4, roflumilast increases the levels of these cyclic nucleotides within cells.
2. Anti-Inflammatory Effects: Increased levels of cAMP and cGMP have anti-inflammatory effects, reducing the production of pro-inflammatory cytokines and chemokines, and inhibiting the migration and activation of immune cells. This helps to decrease inflammation in the lungs and airways.
3. Bronchodilation and Mucus Clearance: By reducing inflammation, roflumilast can also lead to bronchodilation (widening of the airways) and improved mucus clearance, making it easier for patients to breathe and reducing the symptoms of respiratory diseases.